At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 120 enrolled
Drug / intervention
TAK-020 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating TAK-020 and TAK-020 Placebo for Healthy Volunteers. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single- and multiple-doses of TAK-020 in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedApr 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedApr 9, 2015
Enrollment StartMar 18, 2015
Primary CompletionMay 4, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.2 years ago
Interventions
TAK-020drug
TAK-020 oral solution
TAK-020 Placebodrug
TAK-020 placebo-matching oral solution